UroGen (URGN) 2025 Earnings: What Investors Should Know
As UroGen prepares to report 2025 results, investors weigh Jelmyto sales, pipeline progress, and balance-sheet health...
Gain a clear understanding of the time value of money. This concept is crucial for making informed financial decisions.
25,252 articlesAs UroGen prepares to report 2025 results, investors weigh Jelmyto sales, pipeline progress, and balance-sheet health...
A major fund trimmed its stake in a biotech ahead of a June FDA milestone. This article explains what that means for ...
This in-depth analysis digs into the drivers behind foods (bgs) 2025 earnings, exploring brand momentum, debt, and th...
Figma’s latest revenue surge has caught the eye of investors staring at a beaten-down stock. This article breaks down...
Berkshire Hathaway has resumed stock buybacks, purchasing $15 million of its own shares. CEO Greg Abel personally bou...
A software stock that doubled since April caught my eye for reasons beyond hype. In this guide, I explain the growth ...
A major family-office investor has increased its position in Middleby as the company prepares a spin-off. This move o...
A contrarian pick in the under-$10 pile is showing improving margins and debt relief, even as investors overlook it. ...
Alphabet surged over the past year, but a 10% pullback from its high has investors wondering if now is the moment to ...
Adobe Stock sits at a crossroads as the company leans into AI, subscriptions, and enterprise workflows. This guide ex...
As digital transformation accelerates, two distinct paths emerge: AppLovin's AI-powered ad tech vs. Twilio's global c...
Salesforce stock today has been in the spotlight as investors weigh new AI advancements against business execution. T...